SCHEMBL754972

SCHEMBL754972

CC(C)C1=CC(=O)C=C(C(C)C)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.45
CDC25B P30305 1/20 0.45
PTPN1 P18031 1/20 0.43
EEF2K O00418 1/20 0.42
PLK1 P53350 1/20 0.42
PLK2 Q9NYY3 1/20 0.42
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
CES1 P23141 3/20 0.35
HIF1A Q16665 3/20 0.34
EPAS1 Q99814 3/20 0.34
CES2 O00748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL28969836 0.97 CDC25A (0.43) CDC25ACDC25BPTPN1EEF2KPLK1
SCHEMBL13986038 0.83 CDC25A (0.38) CDC25ACDC25BPTPN1EEF2KPLK1
SCHEMBL17935505 0.82 CDC25A (0.45) CDC25ACDC25BPTPN1EEF2KPLK1
SCHEMBL14394520 0.79 CDC25A (0.36) CDC25ACDC25BPTPN1EEF2KPLK1
SCHEMBL9841858 0.79 ALDH1A1 (0.41) CDC25ACDC25BPTPN1EEF2KPLK1
SCHEMBL16503632 0.75 PTPN1 (0.41) CDC25ACDC25BPTPN1EEF2KPLK1
SCHEMBL9454008 0.75 BACE1 (0.64) CDC25ACDC25BPTPN1IDO1
SCHEMBL9778297 0.74 ALDH1A1 (0.38) KDM4EMEN1USP2TP53CYP3A4
SCHEMBL17969767 0.72 EEF2K (0.45) CDC25ACDC25BPTPN1EEF2KPLK1
SCHEMBL6888742 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805398-A Preparation method of ecteinascidin compound 江苏恒瑞医药股份有限公司 2022-07-29 CN claimed
CN-113712917-A Propofol medium-long chain fat emulsion injection and preparation method thereof 远大生命科学(武汉)有限公司 2021-11-30 CN claimed
EP-4419580-B1 METHOD FOR PROMOTING HYDROSILYLATION REACTION TO PREPARE ESTER-FUNCTIONAL SILOXANE OLIGOMERS DOW GLOBAL TECHNOLOGIES LLC (US) 2025-08-27 EP disclosed
US-12398270-B2 Acrylate-functional branched organosilicon compound, method of preparing same, and copolymer formed therewith DOW SILICONES CORPORATION (US) 2025-08-26 US disclosed
US-12378264-B2 Multifunctional organosilicon compound and related methods, compounds, and compositions DOW SILICONES CORPORATION (US) 2025-08-05 US disclosed
US-12371535-B2 Branched organosilicon compound, method of preparing same, and copolymer formed therewith DOW SILICONES CORPORATION (US) 2025-07-29 US disclosed
EP-4172165-B1 PREPARATION OF MULTIFUNCTIONAL ORGANOSILICON COMPOUNDS DOW SILICONES CORP (US) 2025-07-23 EP disclosed
US-20250136763-A1 SILICONE - VINYLESTER FUNCTIONAL COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN PERSONAL CARE COMPOSITIONS DOW SILICONES CORP (US) 2025-05-01 US disclosed
US-20250136625-A1 PROCESS FOR THE PREPARATION OF ORGANIC SILICON COMPOUNDS BASF SE (DE) 2025-05-01 US disclosed
EP-4508106-A1 SILICONE - VINYLESTER FUNCTIONAL COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN PERSONAL CARE COMPOSITIONS Dow Global Technologies LLC (US) 2025-02-19 EP disclosed
EP-4508054-A1 PREPARATION OF ORGANOSILICON COMPOUNDS WITH VINYLESTER FUNCTIONALITY Dow Global Technologies LLC (US) 2025-02-19 EP disclosed
WO-1997015542-A1 PROCESS FOR PURIFYING A 2,6-DIALKYLPHENOL ALBEMARLE CORPORATION (US) 1997-05-01 WO disclosed
US-5591311-A 2,6-DIISOPROPYLPHENOL ALBEMARLE CORPORATION (US) 1997-01-07 US disclosed
EP-0445827-B1 4-Hydroxytetrahydropyran-2-one derivatives useful as cholesterol and lipid reducing agents FUJIREBIO KK (JP) 1996-09-25 EP disclosed
US-5149834-A Anticholesterol agent and enzyme inhibitors, for curing arteriosclerosis FUJIREBIO INC. (JP) 1992-09-22 US disclosed
US-5059598-A Antiinflammatory agents; lipoxygenase inhibitors; arthritis; asthma OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1991-10-22 US disclosed
EP-0445827-A2 4-Hydroxytetrahydropyran-2-one derivatives useful as cholesterol and lipid reducing agents FUJIREBIO INC. (JP) 1991-09-11 EP disclosed
US-4868183-A ANTIINFLAMMATORY, ENZYME INHIBITORS OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1989-09-19 US disclosed
EP-0254259-A2 p-Aminophenol derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1988-01-27 EP disclosed
US-3944632-A Phosphoric acid anilides CIBA-GEIGY CORPORATION (US) 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378264-B2 Multifunctional organosilicon compound and related methods, compounds, and compositions MSR1, OXSR1, RIOX2 CDC25A 2029/4885CDC25B 925/4885PTPN1 3602/4885
US-20250136763-A1 SILICONE - VINYLESTER FUNCTIONAL COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN PERSONAL CARE COMPOSITIONS VCL, FANCF, MMS19 CDC25A 3910/4885CDC25B 4348/4885PTPN1 3434/4885
US-12371535-B2 Branched organosilicon compound, method of preparing same, and copolymer formed therewith OXSR1, BRS3, OXER1 CDC25A 3598/4885CDC25B 2532/4885PTPN1 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.